New drug shows promise for rare high cholesterol condition
NCT ID NCT07489209
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called EDP167 in 20 adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing very high cholesterol. The drug aims to lower harmful cholesterol levels. Participants will receive multiple injections of EDP167 and be monitored for safety and effectiveness over 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to slash Sky-High cholesterol in rare genetic disease
- CRISPR therapy takes aim at stubborn high cholesterol in first human trial
- New study screens newborns for inherited high cholesterol
- New hope for rare cholesterol disease: can evinacumab shrink dangerous plaque?
- Heart attack prevention hope for rare cholesterol disorder